Madrigal Pharmaceuticals Terminates Agreement, Enters New One
Ticker: MDGL · Form: 8-K · Filed: Jul 22, 2025 · CIK: 1157601
| Field | Detail |
|---|---|
| Company | Madrigal Pharmaceuticals, Inc. (MDGL) |
| Form Type | 8-K |
| Filed Date | Jul 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, regulation-fd
TL;DR
Madrigal just terminated one deal and signed another, expect financial shifts.
AI Summary
Madrigal Pharmaceuticals, Inc. announced on July 17, 2025, the termination of a material definitive agreement. The company also entered into a new material definitive agreement and incurred a direct financial obligation. These events are also being disclosed under Regulation FD.
Why It Matters
This filing indicates significant changes in Madrigal's contractual relationships, potentially impacting its financial obligations and strategic partnerships.
Risk Assessment
Risk Level: medium — Changes in material definitive agreements and new financial obligations introduce uncertainty regarding the company's future financial health and operational strategy.
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- SYNTA PHARMACEUTICALS CORP (company) — Former Company Name
- July 17, 2025 (date) — Date of earliest event reported
- 200 BARR HARBOR DRIVE, SUITE 400 (address) — Business and Mail Address
FAQ
What was the nature of the material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but does not provide specific details about its nature or terms.
What is the nature of the new material definitive agreement entered into by Madrigal Pharmaceuticals?
The filing indicates the entry into a new material definitive agreement, but does not specify its terms or purpose.
What is the direct financial obligation incurred by Madrigal Pharmaceuticals?
The filing reports the creation of a direct financial obligation, but does not disclose the amount or specific terms of this obligation.
What is the significance of the Regulation FD Disclosure item?
This indicates that the information being disclosed is intended to prevent selective disclosure of material non-public information to investors.
When did Madrigal Pharmaceuticals change its name from Synta Pharmaceuticals Corp?
Madrigal Pharmaceuticals, Inc. changed its name from Synta Pharmaceuticals Corp on August 15, 2001.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 22, 2025 regarding MADRIGAL PHARMACEUTICALS, INC. (MDGL).